Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 8/20 | 0.79 |
| ▸ | BCHE | P06276 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.78 |
| ▸ | ALDH3A1 | P30838 | 5/20 | 0.78 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.78 |
| ▸ | CDC25A | P30304 | 1/20 | 0.76 |
| ▸ | TGM2 | P21980 | 1/20 | 0.67 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019788 | 0.89 | ALDH1A1 (0.90) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL19297268 | 0.89 | ALDH1A1 (0.62) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL19924204 | 0.88 | CES1 (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL281625 | 0.88 | ALDH1A1 (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL12930216 | 0.86 | CDC25A (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL29613389 | 0.86 | CDC25A (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL282035 | 0.86 | CDC25A (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL28299129 | 0.86 | CDC25A (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL3016105 | 0.86 | CDC25A (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 | |
| SCHEMBL29821573 | 0.86 | CDC25A (1.00) | CES1BCHEALDH1A1ALDH3A1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617889-B1 | Polymers for use as anion exchange membranes | ENVISION ENERGY USA LTD. (US) | 2026-05-05 | — | — | US | claimed |
| EP-3454895-B1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NAJIT TECH INC (US) | 2024-03-27 | — | — | EP | claimed |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2023-12-19 | — | — | US | claimed |
| US-20230346910-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | Najít Technologies, Inc. | 2023-11-02 | — | — | US | claimed |
| US-11633470-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | NAJIT TECHNOLOGIES, INC. (US) | 2023-04-25 | — | — | US | claimed |
| US-20220241395-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | Najít Technologies, Inc. | 2022-08-04 | — | — | US | claimed |
| EP-3454894-B1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | NAJIT TECH INC (US) | 2022-07-27 | — | — | EP | claimed |
| US-11141475-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | NAJIT TECHNOLOGIES, INC. (US) | 2021-10-12 | — | — | US | claimed |
| US-20210196812-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | Najít Technologies, Inc. | 2021-07-01 | — | — | US | claimed |
| US-10744198-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2020-08-18 | — | — | US | claimed |
| US-20200108094-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-09 | — | — | US | claimed |
| US-20190201520-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-04 | — | — | US | claimed |
| EP-3454894-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | Najit Technologies, Inc. (US) | 2019-03-20 | — | — | EP | claimed |
| EP-3454895-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | Najit Technologies, Inc. (US) | 2019-03-20 | — | — | EP | claimed |
| WO-2017197034-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NAJIT TECHNOLOGIES, INC. (US) | 2017-11-16 | — | — | WO | claimed |
| WO-2017197035-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | NAJIT TECHNOLOGIES, INC. (US) | 2017-11-16 | — | — | WO | claimed |
| CN-102432526-A | Chiral 2',5-dicarbonyl-3-aryl spiro[cyclohexane-1,3'-indole]-2,2-dinitrile derivative and preparation method thereof | UNIV SOOCHOW | 2012-05-02 | — | — | CN | claimed |
| US-12617889-B1 | Polymers for use as anion exchange membranes | ENVISION ENERGY USA LTD. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2000038639-A1 | DYEING METHOD USING A SPECIFIC CATIONIC DERIVATIVE AND A COMPOUND SELECTED AMONG A SPECIFIC ALDEHYDE, A SPECIFIC KETONE, A QUINONE AND A DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE DERIVATIVE | L'OREAL (FR) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038641-A1 | DYEING METHOD USING AN ALIPHATIC CATIONIC AMINE AND A ALDEHYDE OR KETONE OR QUINONE OR DI-IMINO-ISOINDOLINE OR 3-AMINO-ISOINDOLONE DERIVATIVES | L'OREAL (FR) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241395-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | DUOX2, DUOX1, TET2 | CES1 2401/4885BCHE 2103/4885ALDH1A1 1349/4885 |
| US-11141475-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | DUOX2, DUOX1, TET2 | CES1 2401/4885BCHE 2103/4885ALDH1A1 1349/4885 |
| US-20210196812-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | OGG1, EIF2AK2, AS3MT | CES1 3140/4885BCHE 2623/4885ALDH1A1 4067/4885 |
| US-20230346910-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | DUOX2, DUOX1, TET2 | CES1 2401/4885BCHE 2103/4885ALDH1A1 1349/4885 |
| US-11633470-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | DUOX2, DUOX1, TET2 | CES1 2401/4885BCHE 2103/4885ALDH1A1 1349/4885 |
| US-20200108094-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | DUOX2, DUOX1, TET2 | CES1 2401/4885BCHE 2103/4885ALDH1A1 1349/4885 |
| US-20190201520-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | OGG1, EIF2AK2, AS3MT | CES1 3175/4885BCHE 2665/4885ALDH1A1 4064/4885 |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | CES1 3140/4885BCHE 2623/4885ALDH1A1 4067/4885 |
| US-10744198-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | CES1 3175/4885BCHE 2665/4885ALDH1A1 4064/4885 |
| US-12617889-B1 | Polymers for use as anion exchange membranes | KCNN3, KCNJ1, KCNH3 | CES1 3853/4885BCHE 4348/4885ALDH1A1 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.